vs
Side-by-side financial comparison of Cytosorbents Corp (CTSO) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
EVERSPIN TECHNOLOGIES INC. is the larger business by last-quarter revenue ($14.9M vs $9.2M, roughly 1.6× Cytosorbents Corp). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -59.5%, a 57.5% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs 0.9%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs 1.3%).
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
CTSO vs MRAM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $14.9M |
| Net Profit | $-5.5M | $-296.0K |
| Gross Margin | 73.7% | 52.7% |
| Operating Margin | -47.5% | 29.0% |
| Net Margin | -59.5% | -2.0% |
| Revenue YoY | 0.9% | 13.2% |
| Net Profit YoY | 27.4% | — |
| EPS (diluted) | $-0.09 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | $9.2M | $14.8M | ||
| Q3 25 | $9.5M | $14.1M | ||
| Q2 25 | $9.6M | $13.2M | ||
| Q1 25 | $8.7M | $13.1M | ||
| Q4 24 | $9.2M | $13.2M | ||
| Q3 24 | $8.6M | $12.1M | ||
| Q2 24 | $8.8M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | $-5.5M | $1.2M | ||
| Q3 25 | $-3.2M | $54.0K | ||
| Q2 25 | $1.9M | $-670.0K | ||
| Q1 25 | $-1.5M | $-1.2M | ||
| Q4 24 | $-7.6M | $1.2M | ||
| Q3 24 | $-2.8M | $2.3M | ||
| Q2 24 | $-4.3M | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 73.7% | 50.8% | ||
| Q3 25 | 70.3% | 51.3% | ||
| Q2 25 | 70.9% | 51.3% | ||
| Q1 25 | 71.1% | 51.4% | ||
| Q4 24 | 68.4% | 51.3% | ||
| Q3 24 | 61.0% | 49.2% | ||
| Q2 24 | 73.5% | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | -47.5% | -7.2% | ||
| Q3 25 | -30.2% | -11.0% | ||
| Q2 25 | -37.6% | -14.9% | ||
| Q1 25 | -44.5% | -14.7% | ||
| Q4 24 | -37.1% | -11.8% | ||
| Q3 24 | -56.1% | -17.5% | ||
| Q2 24 | -40.4% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | -59.5% | 8.1% | ||
| Q3 25 | -33.4% | 0.4% | ||
| Q2 25 | 20.2% | -5.1% | ||
| Q1 25 | -16.9% | -8.9% | ||
| Q4 24 | -82.7% | 9.2% | ||
| Q3 24 | -32.1% | 18.8% | ||
| Q2 24 | -48.6% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | $-0.09 | $0.05 | ||
| Q3 25 | $-0.05 | $0.00 | ||
| Q2 25 | $0.03 | $-0.03 | ||
| Q1 25 | $-0.02 | $-0.05 | ||
| Q4 24 | $-0.14 | $0.07 | ||
| Q3 24 | $-0.05 | $0.10 | ||
| Q2 24 | $-0.08 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.2M | $40.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9M | $70.2M |
| Total Assets | $44.2M | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | $6.2M | $44.5M | ||
| Q3 25 | $7.5M | $45.3M | ||
| Q2 25 | $10.2M | $45.0M | ||
| Q1 25 | $11.6M | $42.2M | ||
| Q4 24 | $3.3M | $42.1M | ||
| Q3 24 | $5.7M | $39.6M | ||
| Q2 24 | $8.5M | $36.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $13.7M | — |
| Q1 26 | — | $70.2M | ||
| Q4 25 | $5.9M | $68.9M | ||
| Q3 25 | $9.0M | $65.8M | ||
| Q2 25 | $11.6M | $64.1M | ||
| Q1 25 | $14.5M | $63.0M | ||
| Q4 24 | $11.1M | $62.6M | ||
| Q3 24 | $13.4M | $59.3M | ||
| Q2 24 | $17.4M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | $44.2M | $84.6M | ||
| Q3 25 | $45.8M | $80.3M | ||
| Q2 25 | $48.0M | $78.9M | ||
| Q1 25 | $50.8M | $80.2M | ||
| Q4 24 | $47.4M | $77.8M | ||
| Q3 24 | $47.8M | $72.6M | ||
| Q2 24 | $53.4M | $64.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.78× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $570.0K |
| Free Cash FlowOCF − Capex | $-4.9M | — |
| FCF MarginFCF / Revenue | -53.4% | — |
| Capex IntensityCapex / Revenue | 1.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | $-4.8M | $2.6M | ||
| Q3 25 | $-2.6M | $881.0K | ||
| Q2 25 | $-1.5M | $5.0M | ||
| Q1 25 | $-3.5M | $1.4M | ||
| Q4 24 | $-2.3M | $3.8M | ||
| Q3 24 | $-2.5M | $2.8M | ||
| Q2 24 | $-4.8M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-4.9M | $-975.0K | ||
| Q3 25 | $-2.6M | $543.0K | ||
| Q2 25 | $-1.5M | $3.0M | ||
| Q1 25 | $-3.5M | $527.0K | ||
| Q4 24 | $-2.4M | $2.1M | ||
| Q3 24 | $-2.6M | $2.8M | ||
| Q2 24 | $-4.8M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | -53.4% | -6.6% | ||
| Q3 25 | -27.3% | 3.9% | ||
| Q2 25 | -16.1% | 22.9% | ||
| Q1 25 | -39.7% | 4.0% | ||
| Q4 24 | -26.3% | 15.8% | ||
| Q3 24 | -30.4% | 22.9% | ||
| Q2 24 | -54.4% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 24.3% | ||
| Q3 25 | 0.2% | 2.4% | ||
| Q2 25 | 0.4% | 15.1% | ||
| Q1 25 | 0.0% | 6.9% | ||
| Q4 24 | 0.8% | 13.2% | ||
| Q3 24 | 1.8% | 0.5% | ||
| Q2 24 | 0.2% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | — | 16.31× | ||
| Q2 25 | -0.78× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.16× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTSO
| Direct | $5.1M | 55% |
| Distributors And Strategic Partners | $4.2M | 45% |
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
